Tebentafusp not checked
Immunocore Ltd · IMCgp100
FollowEvery change as it happens, and a Monday email
Trials
5 active
8 in total · 5 in the EU
What this is
- How it works
- Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager FDA class
- How it’s given
- “Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab”In the company’s words, NCT05549297 on ClinicalTrials.gov
- Tested for
- Advanced Melanoma, Select Advanced Solid Tumors
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.”In the company’s words, NCT05549297 on ClinicalTrials.gov
- Other names
- IMCgp100 · Kimmtrak
Other drugs for Advanced Melanoma
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up1
- Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2028 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | |
| Phase 1/2Active, not recruiting | Oct 2026 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | |
| Phase 2Completed | 13 Oct 2020 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | |
| Phase 1/2Completed | 20 Mar 2020 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | |
| Phase 1/2Withdrawn | 19 Jun 2023 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | |
| Phase 2Authorised | not given | Neoadjuvant Tebentafusp in Patients with Metastatic Uveal Melanoma | |
| Phase 3Authorised | not given | EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial) | |
| Phase 2Authorised | not given | Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026